
|Articles|May 13, 2004
Drug treats PCa patients with bone metastases
Novartis offers zoledronic acid injection (ZOMETA) for the treatmentof patients with documented bone metastases from solid tumors, includingprostate cancer, in conjunction with standard antineoplastic therapy.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
NDV-01 produces robust 9-month results in high-risk NMIBC
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use
4
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
5

















